The integration of biomarkers in chemotherapy offers clinicians the ability to better manage drug toxicities.
In triple-negative breast cancer, the tumor does not express
estrogen receptors, progesterone receptors, or human
epidermal growth factor receptor 2 on immunohistochemical
analysis.